Close

Blockchain Revolutionizes Pharma Operations And Profits

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

The pharmaceutical sector happens to be significant for enhancing and sustaining public health. It is responsible when it comes to exploring, developing, producing, as well as marketing drugs and other pharmaceutical products. That said, it faces loads of challenges ranging from supply chain issues, counterfeit drugs, and data management. These problems can be effectively solved by way of blockchain technology.

The pharma industry, despite its importance in elevating public health, faces a lot of pressing challenges that can hinder its capacity to deliver the best outcomes. These issues can be categorised into the following areas:

Regulatory hurdles

The sector is subject to strict regulations that differ across various jurisdictions. Navigating these complex regulatory challenges can be both costly and time-consuming, thereby delaying the approval and launch of new drugs. 

R&D costs and risks that are high

Manufacturing a new drug involves a substantial financial investment as well as significant risks. The high rate of attrition when it comes to drug development, teamed with an expensive and lengthy clinical trial process, can strain the resources of pharma companies, mostly the smaller ones.

Affordability and access to the market

Making sure that patients have access to drugs at affordable prices is a major concern within the industry. Factors like patient protection, policy on pricing, and reimbursement schemes can notably impact the cost and availability of drugs, especially in low- and middle-income nations.

Ethical challenges

This industry often goes through ethical dilemmas that are related to drug pricing, clinical trial conduct, and promotion. Balancing profit motives with the responsibility to manufacture safe as well as effective treatments for the patient population happens to be an ongoing issue.

All these challenges go on to present set of opportunities for the pharma sector to innovate and adopt new technologies such as Blockchain.

Blockchain happens to be a distributed and decentralised digital ledger that stores information securely. It has a chain of blocks, each of which contains a transaction set or data record. One of the major traits of blockchain tech is its decentralised nature. This means that no single entity, or for that matter, a centralised authority, controls the network. Another important aspect of it is immutability, which means that it is practically impossible for malicious users to go ahead with data tampering.

This technology was initially popularised by Bitcoin, one of the cryptocurrencies. However, today, its application goes beyond crypto. Its capabilities to help efficient data management as well as make transactions secure have sparked interest throughout various industries, such as healthcare and pharma.

It is well to be noted that blockchain technology has umpteen applications within the pharma gamut that offer novel solutions so as to address complex issues and overall elevate efficiency. Let us get into the details of how blockchain technology can be used across the pharmaceutical spectrum.

Supply Chain Management

The pharma supply chain is always regarded as complex and has numerous intermediaries and international border crossings. This complexity can lead to transparency lacunas, bottlenecks when it comes to logistics, as well as enhanced vulnerability in cases of theft and fraud, ultimately having an impact on the affordability as well as availability of the medicines. Blockchain technology can extensively improve transparency as well as traceability across the pharmaceutical supply chain. By developing secure and tamper-proof data for each transaction as well as the movement of the product, the technology helps the stakeholders trace and authorise drugs from their origin point to their final destination by efficiently thwarting counterfeit drugs and at the same time ensuring the safety of patients.

Clinical Trials

Blockchain can play a very significant role when it comes to streamlining the clinical trial processes by safely storing and sharing the trial data, ensuring its integrity and transparency. This helps in enhancing regulatory compliance, helps in faster and more efficient drug development, and in its entirety benefits the patients who happen to be completely dependent on treatments that are life-saving.

Patient data management

The pharma industry goes on to generate huge amounts of sensitive data, like clinical trial results, information about patients, and intellectual property. Making sure of secure storage and retrieval, data sharing happens to be very critical. However, it does remain a crucial issue because of fragmented systems, outdated technologies, and evolving threats pertaining to cyber technology. Blockchain can completely act as a revolutionary technology by way of providing secure and decentralised platform so as to store and also share sensitive information related to patients. All this not only helps with data privacy and security assurance but also enables a better partnership between healthcare providers, thereby enabling more efficient patient care.

Inventory management

Blockchain technology can help in optimising pharma inventory management by offering real-time visibility when it comes to the levels of stock, date of expiration of medicines, as well as their precise location. This elevated transparency helps in better forecasting and, at the same time, reduces the possibility of stockouts and wastage. It also makes sure of the availability of essential medicines for patients.

Application of R & D

Blockchain helps in securely sharing research data and IP, as well as coordinating efforts among pharmaceutical firms, research organisations, and also regulators. This enables more innovation, accelerates the discovery of drugs, and also helps in bringing novel treatments to the market in a swift way.

Counterfeiting prevention

Through the creation of a secure and tamper-proof record of drugs and transactions, blockchain can go on to effectively thwart counterfeiting, thereby protecting patients and also manufacturers from the risks associated with fake drugs.

Product distribution

Blockchain technology can also be put into optimising the distribution of products by way of sharing real-time data on product demand as well as inventory levels, allowing for a more effective allocation of resources and, in a way, helping to reduce the distribution cost as well.

Tracing, Tracking

The usage of blockchain when it comes to tracing as well as tracking pharma products helps in making sure that each product’s journey is effectively monitored right from the manufacturing facility to the hands of the consumer. This level of transparency happens to be very critical when it comes to authenticating the product and preventing counterfeits from entering the market.

Security as well as safety

Blockchain helps in enhancing the safety of the pharma industry and its security as well by helping with an immutable transaction and data record, thereby making it next to impossible for the unauthorised alterations as well as the tampering part to go unnoticed.

Governance of data

The decentralised nature of blockchain and the census mechanism in it enable enhanced data governance by ensuring that the data is stored, managed, as well as shared in a transparent and consistent way across all the people and associates that are involved.

Quality of data

The longevity of blockchain technology makes sure that the data is recorded on it in the most accurate, trustworthy, and reliable way possible. This trait is particularly crucial in a pharma setup when data quality is imperative for compliance with regulations as well as decision-making.

Turnover

The technology related to blockchain can indeed help in reducing pharma turnover by elevating the supply chain processes, reducing waste, and making sure that the products get distributed in the most efficient way. This helps in reducing costs for pharma companies and, at the same time, ensures the availability of drugs to patients in need.

Prescription Drug Monitoring

Blockchain technology can be used to develop secure, tamper-proof records of prescription drug consumption and dispensing, facilitate better monitoring, and analyse patterns of prescribing and the utilisation of drugs.

Challenges and Limitations of Blockchain Tech

Although blockchain technology has immense potential for the pharma sector, its adoption and execution come with limitations and challenges.

Legal Issues

The pharma sector happens to be heavily regulated with strict rules as well as guidelines that govern the various elements of drug manufacturing, development, and distribution. Integrating blockchain technology into the processes requires navigating the challenging regulatory spectrum and making sure compliance with all the laws and regulations. When it comes to the legal framework for data privacy and protection, they must be taken into account when executing blockchain-based solutions for the management of patient data.

Integration of existing systems

The pharma sector depends upon various legacy systems as well as technologies when it comes to managing data and conducting business operations. Integrating blockchain technology into these systems happens to be a challenging and particularly lengthy undertaking that requires substantial investments when it comes to infrastructure, support, and training. For successful execution, it is imperative to overcome any sort of resistance to transformation and ensure a smooth transition towards blockchain-based systems.

Technical Issues

Blockchain technology is relatively new and is still evolving, and there are a certain set of limitations that need to be addressed for its exact application in the pharma industry. For example, scalability happens to be a significant issue since large-scale blockchain implementations may go on to require enough computational resources and energy consumption. Making sure of data privacy on public as well as permission-free blockchains can indeed be quite a challenge.

The Future of Blockchain

The blockchain technology future in the pharma sector looks promising indeed. New innovation and developments are anticipated to emerge, with current limitations being addressed as well as unlocking new possibilities. For example, consensus algorithms, scalability advancements, and privacy protection techniques will likely elevate the performance as well as the applicability of the blockchain across the pharma sector.

Mixing blockchain with other newer technologies such as AI, IoT, and big data can help in availing even bigger transformative solutions. The future of blockchain within the pharmaceutical landscape holds a lot of potential when it comes to collaboration possibilities and innovation.

Conclusion

Blockchain technology can revolutionise the pharmaceutical industry by taking care of critical issues like counterfeit drugs, inefficiencies in the supply chain, and effective management of data. Although there are certain limitations and challenges, its future within the pharma landscape looks very promising indeed.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »